Briefs: Alkem and Krsnaa Diagnostics
Alkem has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.
Alkem has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
Agasta Software is engaged in research, development and commercialization of medical devices
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
Strategic partnership aims to support significant growth of the Ibuprofen product market in Brazil and is backed by Univar Solutions' state-of-the-art Solution Center in São Paulo, Brazil
Laurus Labs has announced that the USFDA completed inspection of the formulations manufacturing facility Unit-2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY
The company has announced net revenue of Rs. 639.8 crore for Q3 FY23 as compared to Rs. 562.08 crore in the corresponding period of the previous year
She is a seasoned leader with nearly 30 years of business leadership and consulting experience with top companies such as Mckinsey and Co, Novartis Pharmaceuticals and Stryker India Pvt. Ltd.
Subscribe To Our Newsletter & Stay Updated